 LAVAL, Québec, April 01, 2020 GLOBE NEWSWIRE -- Acasti Pharma Inc. Acasti or the Company NASDAQ: ACST TSX-V: ACST, a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre omega-3 phospholipid for the treatment of severe hypertriglyceridemia, today announced that it has filed its meeting request with the Food and Drug Administration FDA. The meeting is intended to discuss TRILOGY 1 data, and gain alignment with the FDA on the interpretation of the results. The Company will also seek the FDAs input on Acastis proposed revisions to the pre-specified TRILOGY 2 statistical analysis plan SAP, and explore and agree on a plan for pooling the data from TRILOGY 1 and TRILOGY 2 in support of an NDA filing. 